vs

Side-by-side financial comparison of Energy Vault Holdings, Inc. (NRGV) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $153.3M, roughly 1.4× Energy Vault Holdings, Inc.). Energy Vault Holdings, Inc. runs the higher net margin — -13.5% vs -62.0%, a 48.5% gap on every dollar of revenue. On growth, Energy Vault Holdings, Inc. posted the faster year-over-year revenue change (231.8% vs 25.9%). Over the past eight quarters, Energy Vault Holdings, Inc.'s revenue compounded faster (537.7% CAGR vs 38.0%).

Energy Vault is a global energy storage company specializing in gravity and kinetic energy based, long-duration energy storage products. Energy Vault's primary product is a gravity battery to store energy by stacking heavy blocks made of composite material into a structure, capturing potential energy in the elevation gain of the blocks. When demand for electricity is high, these blocks are lowered with the motors functioning as generators and delivering electricity to the grid.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

NRGV vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.4× larger
RARE
$207.3M
$153.3M
NRGV
Growing faster (revenue YoY)
NRGV
NRGV
+205.9% gap
NRGV
231.8%
25.9%
RARE
Higher net margin
NRGV
NRGV
48.5% more per $
NRGV
-13.5%
-62.0%
RARE
Faster 2-yr revenue CAGR
NRGV
NRGV
Annualised
NRGV
537.7%
38.0%
RARE

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
NRGV
NRGV
RARE
RARE
Revenue
$153.3M
$207.3M
Net Profit
$-20.7M
$-128.6M
Gross Margin
20.6%
Operating Margin
74.3%
-54.7%
Net Margin
-13.5%
-62.0%
Revenue YoY
231.8%
25.9%
Net Profit YoY
66.5%
3.5%
EPS (diluted)
$-0.13
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NRGV
NRGV
RARE
RARE
Q2 26
$153.3M
Q1 26
$21.9M
Q4 25
$207.3M
Q3 25
$33.3M
$159.9M
Q2 25
$8.5M
$166.5M
Q1 25
$8.5M
$139.3M
Q4 24
$33.5M
$164.6M
Q3 24
$1.2M
$139.5M
Net Profit
NRGV
NRGV
RARE
RARE
Q2 26
$-20.7M
Q1 26
$-32.5M
Q4 25
$-128.6M
Q3 25
$-26.8M
$-180.4M
Q2 25
$-34.9M
$-115.0M
Q1 25
$-21.1M
$-151.1M
Q4 24
$-61.8M
$-133.2M
Q3 24
$-26.6M
$-133.5M
Gross Margin
NRGV
NRGV
RARE
RARE
Q2 26
20.6%
Q1 26
21.9%
Q4 25
Q3 25
27.0%
Q2 25
29.6%
Q1 25
57.1%
Q4 24
7.7%
Q3 24
40.3%
Operating Margin
NRGV
NRGV
RARE
RARE
Q2 26
74.3%
Q1 26
-32.5%
Q4 25
-54.7%
Q3 25
-52.8%
-106.9%
Q2 25
-330.7%
-64.8%
Q1 25
-244.8%
-102.6%
Q4 24
-150.6%
-74.3%
Q3 24
-2258.1%
-94.6%
Net Margin
NRGV
NRGV
RARE
RARE
Q2 26
-13.5%
Q1 26
-148.5%
Q4 25
-62.0%
Q3 25
-80.5%
-112.8%
Q2 25
-410.3%
-69.0%
Q1 25
-247.7%
-108.5%
Q4 24
-184.7%
-80.9%
Q3 24
-2217.9%
-95.7%
EPS (diluted)
NRGV
NRGV
RARE
RARE
Q2 26
$-0.13
Q1 26
$-0.20
Q4 25
$-1.28
Q3 25
$-0.16
$-1.81
Q2 25
$-0.22
$-1.17
Q1 25
$-0.14
$-1.57
Q4 24
$-0.41
$-1.34
Q3 24
$-0.18
$-1.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NRGV
NRGV
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$58.3M
$421.0M
Total DebtLower is stronger
$38.0M
Stockholders' EquityBook value
$67.5M
$-80.0M
Total Assets
$312.9M
$1.5B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NRGV
NRGV
RARE
RARE
Q2 26
$58.3M
Q1 26
$55.2M
Q4 25
$421.0M
Q3 25
$32.7M
$202.5M
Q2 25
$22.3M
$176.3M
Q1 25
$21.2M
$127.1M
Q4 24
$30.0M
$174.0M
Q3 24
$51.1M
$150.6M
Total Debt
NRGV
NRGV
RARE
RARE
Q2 26
$38.0M
Q1 26
$160.6M
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Stockholders' Equity
NRGV
NRGV
RARE
RARE
Q2 26
$67.5M
Q1 26
$30.5M
Q4 25
$-80.0M
Q3 25
$80.5M
$9.2M
Q2 25
$90.3M
$151.3M
Q1 25
$114.9M
$144.2M
Q4 24
$126.3M
$255.0M
Q3 24
$179.1M
$346.8M
Total Assets
NRGV
NRGV
RARE
RARE
Q2 26
$312.9M
Q1 26
$298.0M
Q4 25
$1.5B
Q3 25
$281.9M
$1.2B
Q2 25
$248.8M
$1.3B
Q1 25
$217.4M
$1.3B
Q4 24
$183.9M
$1.5B
Q3 24
$252.9M
$1.5B
Debt / Equity
NRGV
NRGV
RARE
RARE
Q2 26
0.56×
Q1 26
5.27×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NRGV
NRGV
RARE
RARE
Operating Cash FlowLast quarter
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NRGV
NRGV
RARE
RARE
Q2 26
Q1 26
$-53.8M
Q4 25
$-99.8M
Q3 25
$-11.7M
$-91.4M
Q2 25
$15.4M
$-108.3M
Q1 25
$-2.7M
$-166.5M
Q4 24
$-34.8M
$-79.3M
Q3 24
$-9.2M
$-67.0M
Free Cash Flow
NRGV
NRGV
RARE
RARE
Q2 26
Q1 26
Q4 25
$-100.8M
Q3 25
$-27.2M
$-92.7M
Q2 25
$6.9M
$-110.7M
Q1 25
$-9.5M
$-167.8M
Q4 24
$-45.4M
$-79.5M
Q3 24
$-36.4M
$-68.6M
FCF Margin
NRGV
NRGV
RARE
RARE
Q2 26
Q1 26
Q4 25
-48.6%
Q3 25
-81.5%
-58.0%
Q2 25
81.6%
-66.5%
Q1 25
-111.5%
-120.5%
Q4 24
-135.5%
-48.3%
Q3 24
-3039.9%
-49.2%
Capex Intensity
NRGV
NRGV
RARE
RARE
Q2 26
Q1 26
Q4 25
0.5%
Q3 25
46.4%
0.8%
Q2 25
98.8%
1.5%
Q1 25
79.5%
1.0%
Q4 24
31.5%
0.1%
Q3 24
2273.1%
1.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NRGV
NRGV

Segment breakdown not available.

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons